THE ANALYSIS OF PLACEBO EFFICIENCY IN THE THERAPY OF ASTHENIC DISORDERS IN SCHIZOPHRENIA

Anna V Yakimets; Svetlana A Zozulya; Igor V Oleichik; Tatiana P Klyushnik

doi:10.17816/nb14160

Neurology Bulletin ›› 2018, Vol. L ›› Issue (4) : 84 -86. DOI: 10.17816/nb14160

Articles

brief-report

THE ANALYSIS OF PLACEBO EFFICIENCY IN THE THERAPY OF ASTHENIC DISORDERS IN SCHIZOPHRENIA

Author information +

History +

PDF

Abstract

Clinical and immunological assessment of placebo effectiveness in patients with schizophrenia in remission with different variants of asthenic symptom-complex was conducted. The results presented confirm the existence of placebo effect and prove placebo effectiveness - treatment for affective-asthenic symptoms in schizophrenia. At the same time this is a short-term effect and it does not occur in the predominance of negative symptomatology in the mental status of patients, which once again demonstrates the irreversible nature of these disorders. In placebo therapy, the relation between the LE and α1-PI inflammatory markers in serum and the change of the mental condition of the patients with affective-asthenic symptoms is established.

Keywords

placebo effect / schizophrenia / endogenous asthenia / inflammatory markers / leukocyte elastase / α1-proteinase inhibitor

Cite this article

Download citation ▾

Anna V Yakimets, Svetlana A Zozulya, Igor V Oleichik, Tatiana P Klyushnik. THE ANALYSIS OF PLACEBO EFFICIENCY IN THE THERAPY OF ASTHENIC DISORDERS IN SCHIZOPHRENIA. Neurology Bulletin, 2018, L(4): 84-86 DOI:10.17816/nb14160

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Аблахатов Ю.И., Лапин И.П. Нестабильность и стабильность выбора цвета и плацебо-реактивность психически больных // Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 1994. №4. С. 80-83.

[2]	Аведисова А.С., Чахава В.О., Люпаева Н.В. Плацебо-эффект в психиатрии (обзор литературы) // Психиатрия и психофармакотерапия. 2004. Т. 06, №2. С. 48.

[3]	Клюшник Т.П., Зозуля С.А., Андросова Л.В. и др. Лабораторная диагностика в мониторинге пациентов с эндогенными психозами («Нейро-иммуно-тест»): Медицинская технология. 2-е изд., испр. и доп. М.: ООО «Издательство «Медицинское информационное агентство», 2016.

[4]	Клюшник Т.П. Зозуля С.А., Олейчик И.В. Биологические маркеры шизофрении: поиск и клиническое применение. Новосибирск: Изд-во ИЭОПП СО РАН, 2017. С. 34-46.

[5]	Лапин И.П. Плацебо и терапия. СПб: Лань, 2000. 224 с.

[6]	Addington D., Addington J., Maticka -Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics // Schizophr Res. 1992. Vol. 6, № 3. Р. 201-208.

[7]	Bergink V., Gibney S.M., Drexhage H.A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. // Biological Psychiatry. 2014. Vol.75, №4. Р. 324-331.

[8]	Colagiuri B., Schenk L.A., Kessler M.D. et al. Colloca The placebo effect: From concepts to genes // Neuroscience. 2015. Vol. 307. Р. 171-190.

[9]	Hall K.T., Loscalzo J., Kaptchuk T.J. Genetics and the placebo effect: the placebome // Trends in Molecular Medicine. 2015. Vol. 21, №5. Р. 285-294.

[10]	Smets E.M. Garssen B., Bonke B., De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue // J Psychosom Res. 1995. Vol. 39, №3. Р. 315-325.

[11]	Vits S., Cesko E., Enck P. et al. Behavioural conditioning as the mediator of placebo responses in the immune system // Philos Trans R Soc Lond B Biol Sci. 2011. Vol. 366, №1572. P. 1799-1807.